Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced

Gilead Sciences' Kite Pharma cell therapy unit is undergoing a business review that will result in layoffs to about 7% of the organization’s workforce.

In a letter sent to staff this week that was obtained by Fierce Biotech, Kite Pharma Executive Vice President Cindy Perettie previewed a “refreshed business strategy” that would better align the unit’s strategic priorities.